64Cu-SARTATE

DRUG3 trials

Sponsors

Clarity Pharmaceuticals Ltd

Conditions

NeuroblastomaNeuroendocrine TumorsRefractory NeuroblastomaRelapsed Neuroblastoma

Early Phase 1

An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours

CompletedNCT04440956

Clarity Pharmaceuticals LtdNeuroendocrine Tumors

Start: 2015-05-21End: 2016-02-25Updated: 2020-06-22

Phase 1

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

TerminatedNCT04023331

Clarity Pharmaceuticals LtdNeuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma

Start: 2020-08-18End: 2025-03-25Updated: 2025-09-16

Phase 2

A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

CompletedNCT04438304

Clarity Pharmaceuticals LtdNeuroendocrine Tumors

Start: 2021-03-02End: 2024-11-26Updated: 2025-02-12

Related Papers

DISCO update: Diagnostic performance of <sup>64</sup> Cu-SARTATE compared to <sup>68</sup> Ga-DOTATATE in patients with known or suspected neuroendocrine tumors.

Journal of Clinical Oncology2026-05-27

DISCO: Diagnostic performance of <sup>64</sup> Cu-SARTATE compared to <sup>68</sup> Ga-DOTATATE in patients with known or suspected neuroendocrine tumors with focus on liver findings.

Journal of Clinical Oncology2026-01-10

A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N

Frontiers in Pediatrics2022-03-1026 citations